Artiva Biotherapeutics (ARTV) Net Cash Flow (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Net Cash Flow data on file, last reported at -$5.7 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 40.34% year-over-year to -$5.7 million in Q1 2026; TTM through Mar 2026 was -$9.5 million, a 40.58% increase from a year earlier, with the FY2025 full-year figure at -$13.4 million, down 0.84% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$5.7 million, down from $1.1 million in the prior quarter.
• Over the last five years, Net Cash Flow for ARTV reached as high as $21.6 million in Q3 2024 and fell as low as -$15.6 million in Q4 2024.
• Historically, Net Cash Flow has averaged -$2.8 million across 4 years, with a median of -$5.3 million in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 107.31% in 2025 and fell as far as 113.68% in 2025.
• Year by year, Net Cash Flow stood at -$12.4 million in 2023, then retreated by 26.37% to -$15.6 million in 2024, then jumped by 107.31% to $1.1 million in 2025, then slumped by 602.27% to -$5.7 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$5.7 million in Q1 2026, $1.1 million in Q4 2025, and -$3.0 million in Q3 2025.